<DOC>
	<DOCNO>NCT00506922</DOCNO>
	<brief_summary>Primary Objective : 1 . To determine efficacy escalate dos pentostatin combination tacrolimus methotrexate prevention acute graft-versus-host disease ( GVHD ) context unrelated donor one antigen mismatch related donor transplantation . Secondary Objectives : 1 . To determine safety escalate dos pentostatin combination tacrolimus methotrexate . 2 . To reduce incidence acute GVHD follow transplant unrelated donor 40 % . 3 . To document blood level tacrolimus combine pentostatin .</brief_summary>
	<brief_title>Phase I/II Study Pentostatin Combined With Tacrolimus Mini-Methotrexate GVHD Prevention After MUD BMT</brief_title>
	<detailed_description>During study , patient blood , urine , bone marrow , X-ray exam do . These exam do monitor result transplantation . Blood test do daily patient hospitalize . Patients study receive chemotherapy and/or radiation treat malignancy prevent graft rejection . This give infusion donor cell . Patients myeloid leukemia may receive busulfan vein ( IV ) 4 day cyclophosphamide vein 2 day . Patients lymphoid malignancy may receive thiotepa vein one dose , cyclophosphamide vein 2 day , irradiation 4 day . Other chemotherapy treatment may use donor cell infusion . IV injection give previously insert catheter extend vena cava ( large chest vein ) . Patients randomly pick ( toss coin ) receive one five different treatment . This do learn benefit pentostatin treatment appropriate dose . Four treatment use different dose schedule pentostatin . The fifth treatment group receive pentostatin . All patient receive tacrolimus methotrexate . Pentostatin give vein 4 dos first month transplant . Tacrolimus ( FK506 ) give vein mouth 6 month . Methotrexate give vein 3 dos first week transplant . Patients receive blood platelet transfusion transplant . The number transfusion depend quickly blood cell count return normal range . Patients remain hospital 4-6 week Houston area 100 day transplant . This investigational study . All study drug commercially available . Pentostatin use GVHD prevention outside study . A total 150 patient take part study .</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>1 . Patients receive allogeneic hematopoietic transplant unrelated donor one antigen mismatch related donor . 2 . Patients AML , ALL , Hodgkin 's disease , MDS ( include CMML ) , CML late chronic accelerate phase blast crisis , lymphoma first later relapse . 3 . Patients must bilirubin &lt; 1.5 mg/dL , DLCO &gt; 50 % predict , LVEF &gt; 45 % performance status 0 1 . 4 . Candidates must creatinine level &lt; 1.5 mg/dL calculate creatinine clearance &gt; 60 ml/min . 1 . HIV seropositivity 2 . Uncontrolled infection 3 . Pregnancy 4 . Candidates receive chemotherapy hydroxyurea Gleevec least 3 week prior treatment . Maintenance therapy oral chemotherapy acceptable . Treatment day define transplant day +8 , date first dose pentostatin . 5 . Diagnosis myelofibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>GVHD Prevention</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Pentostatin</keyword>
</DOC>